Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Neovascular (Wet) AMD”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Ended earlyNCT01624636
What this trial is testing

Safety and Tolerability of Intravenous LFG316 in Wet Age-related Macular Degeneration (AMD).

Who this might be right for
Neovascular Age-related Macular Degeneration
Novartis Pharmaceuticals 1
Early research (Phase 1)Not Yet RecruitingNCT07764965
What this trial is testing

Evaluation of PAN-90806 Eye Drops in Healthy Subjects

Who this might be right for
Wet Age Related Macular DegenerationNeovascular (Wet) Age-Related Macular Degeneration
Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd. 20
Testing effectiveness (Phase 2)Study completedNCT03345082
What this trial is testing

A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD

Who this might be right for
Neovascular Age-related Macular Degeneration
Opthea Limited 366
Not applicableStudy completedNCT00656903
What this trial is testing

High Speed Indocyanine Green Angiography Findings in Ranibizumab Treatment for Wet Age-related Macular Degeneration

Who this might be right for
Macular Degeneration
National Eye Institute (NEI) 75
Early research (Phase 1)Study completedNCT02022540
What this trial is testing

Phase 1 Study of Topical Ocular PAN-90806 for Neovascular AMD

Who this might be right for
Age-Related Macular Degeneration (AMD)
PanOptica, Inc. 50
Post-approval studies (Phase 4)Study completedNCT02581891
What this trial is testing

Managing Neovascular (Known as "Wet") Age-related Macular Degeneration Over 2 Years Using Different Treatment Schedules of 2 mg Intravitreal Aflibercept Injected in the Eye

Who this might be right for
Macular Degeneration
Bayer 287
Testing effectiveness (Phase 2)Study completedNCT05275205
What this trial is testing

Safety, Tolerability, and Efficacy Study of UBX1325 in Patients With Neovascular Age-Related Macular Degeneration (ENVISION)

Who this might be right for
Neovascular Age-related Macular Degeneration
Unity Biotechnology, Inc. 51
Very early researchNot Yet RecruitingNCT06888492
What this trial is testing

To Evaluate the Safety and Preliminary Efficacy of Intravitreal EXG202 Injection in Patients with Wet (neovascular) Age-related Macular Degeneration (wAMD)

Who this might be right for
Wet Age-related Macular Degeneration (wAMD)Wet Age-related Macular Degeneration
Guangzhou Jiayin Biotech Ltd 8
Very early researchNot Yet RecruitingNCT07728981
What this trial is testing

Biomarkers, Effectiveness, and Safety of Aflibercept 8mg Modified Fixed Dose Regimen in Treatment-Naïve nAMD Patients

Who this might be right for
Neovascular Age-Related Macular Degeneration (nAMD) Wet AMD
Tianjin Medical University Eye Hospital 49
Testing effectiveness (Phase 2)Study completedNCT04126317
What this trial is testing

Safety, Tolerability, and Efficacy of Aflibercept in Patients With Neovascular Age-Related Macular Degeneration

Who this might be right for
Neovascular (Wet) Age-Related Macular Degeneration
Regeneron Pharmaceuticals 106
Post-approval studies (Phase 4)UnknownNCT00813891
What this trial is testing

Efficacy of Ranibizumab in Combination With Photodynamic Therapy for Wet Age-Related Macular Degeneration

Who this might be right for
Macular DegenerationVisual Acuity
McGill University Health Centre/Research Institute of the McGill University Health Centre 180
Not applicableStudy completedNCT05111743
What this trial is testing

Real-world Evaluation of Brolucizumab for the Treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD) (Komodo Health)

Who this might be right for
Age-related Macular Degeneration (AMD)
Novartis Pharmaceuticals 9,261
Not applicableStudy completedNCT05110209
What this trial is testing

Real-world Evaluation of Prevalence of Ocular Adverse Events in Patients With Neovascular (Wet) Agerelated Macular Degeneration (AMD) Who Received Anti-VEGF Agents (IRIS Registry)

Who this might be right for
Age-related Macular Degeneration (AMD)
Novartis Pharmaceuticals 331,541
Large-scale testing (Phase 3)Ended earlyNCT04049266
What this trial is testing

Evaluate the Efficacy and Safety of KSI-301, an Anti-VEGF Antibody Biopolymer Conjugate, Versus Aflibercept in Patients With Neovascular (Wet) Age-Related Macular Degeneration.

Who this might be right for
Wet Macular Degeneration
Kodiak Sciences Inc 559
Not applicableStudy completedNCT07744984
What this trial is testing

The Efficacy of Home OCT Supported Management in Patients Diagnosed With Neovascular-AMD and Undergoing a Drug Switch to Faricimab

Who this might be right for
Age-Related Macular Degeneration (AMD)Neovascular Age-Related Macular Degeneration (nAMD) Wet AMD
Rabin Medical Center 12
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07798375
What this trial is testing

Evaluate the Efficacy and Safety of VIS-101 in Participants With Neovascular Age-Related Macular Degeneration

Who this might be right for
Neovascular Age Related Macular Degeneration(nAMD)
Everest Medicines (China) Co.,Ltd. 244
Large-scale testing (Phase 3)Looking for participantsNCT07317934
What this trial is testing

Efficacy and Safety of LX102 Gene Therapy in Patients With Neovascular Age-related Macular Degeneration (nAMD) (STELLAR)

Who this might be right for
Neovascular Age-Related Macular Degeneration (nAMD)Wet AMD
Innostellar Biotherapeutics Co.,Ltd 388
Testing effectiveness (Phase 2)Ended earlyNCT00464347
What this trial is testing

TAC-PF, Avastin® in Combination With Photodynamic Therapy to Treat Age Related Macular Degeneration

Who this might be right for
Age-Related Macular Degeneration
National Eye Institute (NEI) 100
Early research (Phase 1)Study completedNCT02061865
What this trial is testing

Phase 1 Safety Study With Intravitreal (IVT) REGN2176-3 in Patients Aged 50 Years and Older With Wet AMD

Who this might be right for
Neovascular Wet Age-related Macular Degeneration (AMD)
Regeneron Pharmaceuticals 12
Early research (Phase 1)Study completedNCT07484074
What this trial is testing

A Phase 1b Study to Assess the Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy of Intravitreal OLN324

Who this might be right for
Diabetic Macular Edema (DME)Neovascular (Wet) Age-Related Macular Degeneration
Ollin Biosciences, Inc. 164
Next Page